Goldman Sachs analyst Graig Suvannavejh initiated Insmed with a Buy rating and a price target of $30, saying the stock offers an attractive entry point at 50% below its 52-week high as a de-risked commercial-stage biopharma with "significant" potential for expansion. The analyst contends that Insmed's lead orphan lung disease product Arikayce is well-positioned with it's early life cycle stage, no obvious competition and the potential for both geographic and label expansion. Suvannavejh adds that the company's INS1007 also has pipeline potential while garnering "little investor attention".